Alleged Stroke Trial Misconduct; Ultrasound Tx for Severe AS; Farxiga’s eGFR Drops

Derick Alison
Derick Alison
4 Min Read

The American Heart Association (AHA) unveiled its PREVENT risk calculator for estimating heart attack, stroke, and heart failure risk over 10 or 30 years for people ages 30 and older. The tool removes race from the calculation and would supplant the Pooled Cohort Equations.

Whistleblowers point to scientific misconduct and an early uptick in mortality in studies of 3K3A-activated protein C for acute ischemic stroke. (Science)

Serum lipoprotein(a) concentrations plummeted with administration of the short interfering RNA therapy lepodisiran in a dose-finding trial. (JAMA)

A non-invasive ultrasound therapy appeared safe and feasible based on a high-risk patient cohort with severe symptomatic aortic valve stenosis. (The Lancet)

For people with atrial fibrillation (Afib), the dual-acting factor XI/XIa inhibitor abelacimab cut bleeds compared with rivaroxaban (Xarelto) in the AZALEA-TIMI 71 study highlighted by the AHA.

People with sleep apnea tend to be at higher risk of incident Afib. (Journal of the American Heart Association)

Two to 4 weeks of cessation of combined hormonal contraceptives was enough for the excess risk of venous thromboembolism to wane sufficiently. (Blood)

For CPR, proper lung inflation during bag-valve-mask ventilation was strongly associated with improved return of spontaneous circulation, survival, and survival with favorable neurological outcome. (Circulation)

ECG changes over time are a marker for sudden cardiac arrest, suggesting value in combining dynamic risk with static risk for better identification of high-risk individuals in the future. (European Heart Journal)

A decline in eGFR in the first month after initiation of the SGLT2 inhibitor dapagliflozin (Farxiga) did not portend cardiovascular or kidney events in patients with heart failure and mildly reduced or preserved ejection fraction. (JAMA Cardiology)

In the DAPA-MI trial, dapagliflozin had no clinical benefit on select survivors of acute myocardial infarction who did not have chronic heart failure at baseline. (NEJM Evidence)

Medtronic announced that it reduced false alerts from LINQ II insertable cardiac monitors thanks to artificial intelligence algorithm enhancements.

Researchers established parameters indicating normal and disease-specific changes on exercise echocardiography of the pulmonary circulation and the right ventricle. (Journal of the American College of Cardiology)

There are persistently high 30- and 60-day readmissions for pediatric heart failure. (JACC: Heart Failure)

The Institute for Clinical and Economic Review handed sotatercept a health-benefit price benchmark of $18,700-$36,200 per year, or the maximum it should cost as a treatment for pulmonary arterial hypertension.

Inflammation of the placenta during pregnancy was linked to cardiovascular and psychiatric conditions for the child in subsequent adulthood. (Nature Communications)

Does treatment of benign prostatic hyperplasia with α-blockers confer excess cardiovascular events? (JAMA Network Open)

Mount Sinai announced that its researchers are sending bioengineered human heart muscle cells into space for the first time so that the effects of microgravity can be studied.

  • author['full_name']

    Nicole Lou is a reporter for MedPage Today, where she covers cardiology news and other developments in medicine. Follow

Source link

Share this Article
Leave a comment
adbanner